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GENERALFEATURES OFGASTROINTESTINAL
STROMALTUMORS
Gastrointestinal stromal tumors (GISTs) are mes-
enchymal tumors of the gastrointestinal tract that differ-
entiate towards interstitial cells of Cajal or their precur-
sors; they are generally KIT (CD117)-positive, and
display KIT or PDGFRA gene mutations (1,2). These
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ABSTRACT
Introduction: gastrointestinal stromal tumors (GISTs) are spe-
cific, generally KIT (CD117)-positive, mesenchymal tumors of the
digestive tract displaying KIT or PDGFRA gene mutations. Clini-
cally, they tend to present as solitary tumors of the intestinal wall;
more rarely, multiple tumors may occur in one or more organs.
Objective: to review the morphological, immunohistochemi-
cal and molecular features of multiple, non-metastatic forms of
GIST.
Sources: review of the literature on Medline, and authors’
own experience.
Conclusions: multiples GISTs may occur in three different
contexts: as spontaneous lesions (in both adults and children); due
to familial GIST syndrome (autosomal dominant inheritance); or
in association with specific syndromes (e.g. Carney’s triad, Car-
ney-Stratakis syndrome, type I neurofibromatosis). Outside these
contexts, the existence of multiple GISTs is deemed to be the re-
sult of tumor metastasis, and therefore indicative of advanced-
stage disease. Clinicians need to be aware of these variants,
whose prognosis and treatment differ.
Key words: Gastrointestinal stromal tumors. GIST. Carney’s tri-
ad. Carney-Stratakis syndrome. Type I neurofibromatosis. Famil-
ial GIST syndrome. Pediatric GIST.
RESUMEN
Introducción: los tumores del estroma gastrointestinal (GIST)
son neoplasias mesenquimales del tubo digestivo que generalmen-
te expresan el receptor KIT (CD117) y muestran mutaciones en
los genes KIT o PDGFRA. Aunque la forma de presentación clíni-
ca habitual es como una neoplasia mural solitaria, excepcional-
mente pueden presentarse formas múltiples en el mismo o dife-
rente órgano.
Objetivo: revisar las características morfológicas, inmunohis-
toquímicas y moleculares de las formas de GIST múltiples no me-
tastásicos.
Fuentes: revisión de la literatura en Medline y la propia expe-
riencia.
Conclusiones: los GIST múltiples pueden presentarse en tres
contextos diferentes: lesiones espontáneas (del adulto o de la edad
infantil); síndrome familiar propio (transmitido con herencia auto-
sómica dominante); y lesiones asociadas a síndromes específicos
(tríada de Carney, síndrome de Carney-Stratakis, y neurofibroma-
tosis tipo I). Fuera de estos ámbitos, se interpreta que todo GIST
múltiple es el resultado de siembras tumorales metastásicas y, por
tanto, corresponde a enfermedad avanzada. Estas variantes deben
ser conocidas por el clínico dado las connotaciones pronósticas y
terapéuticas que ello conlleva.
Palabras clave: Tumores del estroma gastrointestinal. GIST.
Tríada de Carney. Síndrome de Carney-Stratakis. Neurofibroma-
tosis tipo I. Síndrome de GIST familiar. GIST pediátrico.
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tumors have recently prompted particular interest due to
their good response to new targeted therapies (imatinib
mesylate, Glivec®, Novartis) (3). They generally arise as
solitary tumors of the stomach (50%), small intestine
(25%), large intestine (10%) or esophagus (5%) (Fig.
1); in 10% of cases they occur outside the gastrointesti-
nal tract (EGIST: extra-gastrointestinal stromal tumors),
in the mesenterium, epiploon and –more rarely– appen-
dix, gall bladder or pancreas (1,4). Epidemiological
studies report an annual incidence of 6.8-19.6 per mil-
lion inhabitants, depending on the countries surveyed
(5), affecting men and women roughly equally, over a
wide age range; however, 75% of cases occur in adults
aged over 50 (6). The following clinical signs and
symptoms may be observed: fatigue, abdominal pain,
dysphagia, feeling of fullness, hematemesis or melena
(1,4,5,7,8). Smaller GISTs are often incidental findings
during surgery, radiological studies or endoscopy (1).
At histological examination, tumors tend to display
spindle cell, epithelioid or mixed cell morphology (Fig.
2). Immunohistochemical features include positivity for
CD117 (95%), CD34 (60-70%), smooth muscle actin
(30-40%), S-100 protein (5%), and more rarely desmin
(1-2%) (1,4) (Fig. 3); it should be stressed that 5% of
GISTs do not show positivity for CD117. Two new tis-
sue markers (DOG-1, PKCθ) have been identified, pro-
viding specificity and sensitivity equal to or greater than
those of CD117 (9-15). Both proteins are selectively ex-
pressed on interstitial cells of Cajal (ICC), but their re-
lationship with the KIT receptor is unknown. Molecular
studies have revealed mutually exclusive mutations in
KIT (60-80%) and PGFRA (5-10%) genes (1,4,5,16).
Recently, BRAF mutations were detected in 13% of cas-
es bearing no KIT/PPDGFRA (wt KIT/PDGFRA) muta-
tions (16). Approximately 20-25% of gastric and 40-
50% of small intestinal GISTs are clinically malignant.
Local recurrences and metastases (early and late) com-
monly develop in the abdominal cavity and liver; more
rarely, in bone, soft tissue and skin (1). Lymph-node
metastases are extremely rare, and primarily affect chil-
dren (1). Tumor size, mitotic activity and location are
the major prognostic factors (17-19).
Fig. 1. Gastric gastrointestinal stromal tumor. A. Protruding lesion in the mucosa with central ulceration. B. Section showing hourglass growth pattern,
focal necrosis and bleeding.
Diagnosis of GIST requires a basic immunohistochemi-
cal examination including the following markers: CD117,
CD34, smooth muscle actin, desmin and S100 protein;
these markers, routinely used in histology laboratories, en-
able differential diagnosis with respect to morphologically
similar tumors (mainly leiomyoma/leiomyosarcoma and
schwannoma) (Fig. 4). Molecular analysis is recommended
for the diagnosis of CD117-negative tumors, and also as the
basis for targeted therapy, since patients with GISTs harbor-
ing KIT exon 9 mutations need to double the dosage of ima-
tinib (20), while those displaying the PDGRFA exon 18
mutation D842V fail to respond to this drug (21,22). In
view of its specialized nature, molecular analysis is current-
ly performed by reference centers.
MULTIPLE GASTROINTESTINAL STROMAL
TUMORS
In very rare cases, multiple GISTs may be detected in
one or more organs; this is not necessarily an indicator of
greater aggressivity. Digestive specialists need to be
aware of these rare forms, whose prognosis and treatment
differ from those of conventional GISTs. Multiple tumors
may arise in three clinical contexts: sporadic tumor for-
mation (in both pediatric and adult patients); familial
GIST syndrome (autosomal dominant inheritance); or as
an additional component of certain syndromes (Carney’s
triad, Carney-Stratakis syndrome and type I neurofibro-
matosis). The differential diagnosis of these syndromes is
based mainly on clinical and genetic studies, rather than
on morphological, immunohistochemical or molecular
findings.
Multiple sporadic GISTs in adults
Multiple sporadic GISTs are generally characterized by
the presence of two or three lesions, at the same site or in
different sites, showing different molecular alterations in
the same gene (KIT) (23,24), or in KIT and PDGFRA genes
(25,26). Agaimy et al. (27) recently analyzed 11 patients
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Fig. 2. Common histological patterns. A. Spindle cell morphology HE 40X. B. Epithelioid cell morphology. HE 60X.
aged over 70, with small sclerosing tumors or tumorlets (2-
4 each) in the proximal stomach; tumors were incidental
findings at autopsy or during surgery. All displayed spindle-
cell morphology, and all were CD117+ and CD34+. In all
but one case, individual lesions from the same patient dis-
played different KIT mutations (Table I). The presence of
multiple sporadic lesions in the same patient points to the
existence of distinct subsets of interstitial cells of Cajal or
their precursors in different locations (field carcinogenesis
theory); molecular analysis is therefore essential in order to
distinguish metastatic from non-metastatic lesions (27).
Multiple sporadic GIST in children and adults
under 30
GISTs in pediatric and adolescent patients account for
1-2% of all GISTs, and differ in certain respects from
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Fig. 3. A. CD117 positivity tends to be strong and diffuse, and may be detected in both membrane and cytoplasm. 40X B. CD34 positivity is generally
strong, and is detected in cell membrane. 20X. C. Smooth muscle actin expression tends to be focal and cytoplasmic. 20X. D. S100 protein positivity
tends to be focal, and involves both the cytoplasm and the nucleus. 40X.
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those recorded in adults (28). Molecular analysis has
been performed in around 75 cases, and KIT/PDGFRA
mutations have been detected in 11-15% of these (28-30).
Pediatric GISTs are more prevalent in females (70%), oc-
cur prefentially in the stomach (88%), tend to be multifo-
cal (81%), display epithelioid or mixed cell morphology
(82%), and generally lack both KIT/PDGFRA mutations
(88%) and interstitial cell of Cajal hyperplasia (100%).
By contrast, the few pediatric GISTs with KIT or
PDGFRA mutations have very different features: preva-
lence is greater in males, lesions tend to be unifocal, and
usually occur in extragastric locations, and spindle-cell
morphology is found in all cases (28,29); in other words,
they share many of the features of spontaneous adult tu-
mors.
Immunohistochemically, pediatric GISTs consistent-
ly overexpress CD117 (28-30) and DOG1 (10). Unlike
in adults, pediatric GISTs tend to follow an indolent
course, and are associated with better survival rates,
despite the high rate of intra-abdominal and even
lymph-node metastasis (28-30). The transcriptional
signature is distinct from that of adult GISTs; the top-
ranked genes overexpressed in the pediatric subset are
CRLF1, BAALC, FGF4, PLAG1, and IGF1R. Tumor
progression to malignancy is also different, and proba-
bly results from gene promoter methylation; unlike in
adults, sequential chromosomal deletions (at 14q and
22q) and LOH are not common; by contrast, chromoso-
mal additions (X, 1q, 5p, 8q, 9p, 12p, 13q, 18p, 19q)
and amplifications (1q and 19p) are more frequent
(28,29). The major differences between adult and pedi-
atric subsets are shown in table II.
Although GIST is a heterogeneous entity in adults
aged under 30, most cases display the predominance of
mutation and the clinicoapathological features of the
adult tumor (28).
Familial GIST syndrome
This is an extremely rare disorder. To date, a clear au-
tosomal dominant inheritance pattern associated with one
or more GISTs affecting two or more family members
has been reported in only 20 families (31-49) (Table III).
The phenotypic syndrome varies considerably, and may
include –in addition to multiple, generally benign GISTs
appearing in middle age– hyperpigmentation, urticaria
pigmentosa and dysphagia (32,33). Germline mutations
generally affect the KIT gene (31-46), though cases of
PDGFRA germline mutations have also been reported
(47-49). Skin alterations are common in patients with
KIT exon 8 (31) and exon 11 mutations (32-36,39). Dys-
phagia, caused by esophageal dysmotility related to ICC
hyperplasia, is observed in patients with KIT exon 8 (31)
and exon 17 mutations (44,45).
KIT exon 17 mutations, which are very rare in spo-
radic GIST, have been reported in three cases of famil-
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Table I. Multiple sporadic GISTs in adults
Elderly adults
Two or three synchronous lesions
Predilection for the stomach
Spindle cell morphology
CD117 and CD34 positive
Different mutations in KIT or in KIT and PDGFRA
Table II. Multiple sporadic GISTs in children and young
adults. Differential features
Children Adults
Frequency 89% 11%
Presentation Stomach, multiple, Small bowel/stomach,
>> female solitary >>male
KIT/PDGFRA mutations No Yes
Histology Epithelioid Spindle/epithelioid
Clinical progress Indolent Progressive
ICC hyperplasia No Yes
Cytogenetics Minimal changes Deletions
(additions and 14q, 1p, 9p, 22q
amplifications)
Transcriptional signature CRLF1, BAALC, FGF3, KIT, CD34, PKCθ,
PLAG1, IGF1R… DOG-1,…
Carney’s triad Some None
ICC: interstitial cells of Cajal.
Table III. Familial gastrointestinal stromal tumor syndrome
Gene Exon Mutation type Clinical findings
(No. cases)
KIT Exon 8 Asp419del* (1) GIST (31), achalasia, mastocytosis
Exon 11 Trp557Arg (2) Pigmentation, GIST (32,33)
Val559Ala (4) Pigmentation, urticaria
pigmentosa, GIST (34-36)
Val560Gly (1) GIST (37)
Val560del (1) GIST (38)
Gln575_Leu576dup (1) Pigmentation, GIST (39)
Asp579del (2) GIST (40,41)
Exon 13 Lys642Glu (2) GIST (42,43)
Exon 17 Asp820Tyr (2)
Asn822Tyr (1) Achalasia, GIST (44,45)
GIST (46)
PDGFRA Exon 12 Tyr555Cys* (1) GIST (47)
Asp561Val (1) Fibrous polyps, lipomas, GIST (48)
Exon 18 Asp846Tyr (1) GIST (49)
GIST: gastrointestinal stromal tumor. *Mutations reported only in familial GIST.
ial GIST; two at codon 820 (Asp820Tyr) (44,45) and
one at codon 822 (Asn822Tyr) (46). The specific type
of mutation is generally the same as that found in spo-
radic tumors, with two notable exceptions: KIT (exon
8) Asp419del (31) and PDGFRA (exon 12) Tyr555Cys
(47). Pasini et al. (48) recently reported the unusual
case of a patient carrying a germline PDGFRA muta-
tion Asp561Val who developed multiple fibrous polyps
(> 100) in the intestine, stomach, duodenum and ce-
cum, lipomas in the duodenum and jejunum and gastric
GIST, with no associated ICC hyperplasia. Gastric and
duodenal fibrous tumors were CD34+, CD117-, PKCθ-
and PDGFRA+; whilst the two gastric GISTs were
CD117+, CD34+, PDGFRA+, PKθ+.
GIST associated with Carney’s triad and the Carney-
Stratakis syndrome
Carney’s triad is a non-familial condition preferential-
ly affecting women and combining the presence of multi-
focal epithelioid gastric GIST with the metachronous or
synchronous occurrence of paraganglioma and pul-
monary chondroma, although the conjunction of the three
lesions is not necessary for diagnosis (50). Molecular
studies to date have failed to reveal specific genetic alter-
ations (51). Female predisposition, multifocal gastric lo-
cation and wtKIT/PDGFRA genotype are findings which
overlap considerably with clinicopathological features of
pediatric GIST (28), suggesting that pediatric forms may
represent a forme fruste of Carney’s triad; longer follow-
ups appear to confirm this suspicion, at least in some cas-
es (28).
The Carney-Stratakis syndrome is a similar condition,
in that it combines gastric GISTs and paragangliomas;
however, it differs from Carney’s triad in that it affects
men and women with equal frequency, displays an auto-
somal dominant inheritance pattern and is not associated
with pulmonary lesions; moreover, molecular analysis re-
veals germline mutations of the genes coding for SDH
subunits B, C and D) (52,53). The main differential fea-
tures of the two conditions are shown in table IV.
GIST associated with type I neurofibromatosis
The range of gastrointestinal lesions associated with
type 1 neurofibromatosis (NF1) includes: a) hyperpla-
sia of nerve plexuses; b) GIST; c) endocrine tumors of
the duodenum and periampullary region (somatostatin-
oma); and d) other tumors of varied histogenesis (54).
The incidence of GIST in patients with NF1 is 7% (55).
Most reported cases occur in middle-aged or elderly
patients; tumors are multiple and often microscopic,
are located in the small intestine (ileum and jejunum),
and are accompanied by hyperplasia of the interstitial
cells of Cajal (Fig. 5). Histologically, tumors display
spindle-cell morphology, with few mitotic figures and
frequent skeinoid fibers; they are immunohistochemi-
cally positive for CD117, DOG-1 and PKCθ (10,56-62)
(Fig. 6). However, immunostaining for S100 protein
yields variable results: some authors report low expres-
sion (58,61,62) or no expression at all (54,57) whilst
others have observed positivity for S100 in up to 64%
of cases (57). Molecular analysis in the seven largest
cohorts indicates an incidence of KIT and PDGFRA
mutations of 4.1% (6/145) and del 1.7% (2/116), re-
spectively; some of these may be random mutations,
since they are not observed in sporadic GISTs (57). A
recent study has reported loss of heterozygosity at 14q
(87.5%) and at 22q (41.7%), together with activation of
the Ras-MAPK pathway, probably associated with in-
activation of the NF1 gene (62). The main features of
GISTs associated with type 1 neurofibromatosis are
shown in table V.
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Table IV. Carney’s triad and Carney-Stratakis syndrome.
Differential features
Carney’s triad Carney-Stratakis syndrome
Inheritance Sporadic Dominant autosomal
Sex >>> women Women and men
Synchronous/metachronous
clinical signs Gastric epithelioid GIST Gastric epithelioid GIST
Paraganglioma Paraganglioma
Pulmonary chondroma
Molecular changes Unknown SDH mutations
(subunits B, C, D)
>>>>: large majority. GIST : gastrointestinal stromal tumor.
Fig. 5. Type 1 neurofibromatosis. Resected small bowel specimen
showing two independent tumors separated by a segment of normal
tissue.
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